{
    "clinical_study": {
        "@rank": "159619", 
        "arm_group": {
            "arm_group_label": "Cohort"
        }, 
        "brief_summary": {
            "textblock": "This multicenter, observational study will evaluate the correlation between clinical and\n      biological factors and International Prognostic Index (IPI) as prognostic factors in\n      patients with diffuse large B-cell lymphoma receiving first-line treatment with\n      MabThera/Rituxan (rituximab) in combination with CHOP chemotherapy. Eligible patients\n      receiving treatment according to standard of care and local guidelines will be followed for\n      the duration of treatment (approximately 8 months) and during 1 year of follow-up."
        }, 
        "brief_title": "An Observational Study of MabThera/Rituxan (Rituximab) in Combination With CHOP Chemotherapy in First-Line in Patients With Diffuse Large B-Cell Lymphoma", 
        "completion_date": {
            "#text": "August 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Lymphoma, B-Cell", 
        "condition_browse": {
            "mesh_term": [
                "Lymphoma", 
                "Lymphoma, B-Cell", 
                "Lymphoma, Large B-Cell, Diffuse"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Adult patients, >18 years of age\n\n          -  Patients with diagnosed diffuse large B-cell lymphoma in first-line treatment with\n             R-CHOP\n\n        Exclusion Criteria:\n\n          -  Prior chemotherapy treatment for diffuse large B-cell lymphoma\n\n          -  Contra-indications or exclusion criteria according to the Summary of Product\n             Characteristics for MabThera/Rituxan"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "Patients with diffuse large B-cell lymphoma treated in first line with R-CHOP"
            }
        }, 
        "enrollment": {
            "#text": "140", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 7, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01724294", 
            "org_study_id": "ML28497"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "February 3, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Bucuresti", 
                    "country": "Romania", 
                    "zip": "030171"
                }
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Romania"
        }, 
        "number_of_groups": "1", 
        "official_title": "Non-interventional, Post-marketing Study to Evaluate the Correlation Between Clinical and Biological Factors and IPI as Prognostic Factors in Patients With DLBCL in First Line Treatment With R-CHOP", 
        "overall_contact": {
            "email": "global.rochegenentechtrials@roche.com", 
            "last_name": "Reference Study ID Number: ML28497 www.roche.com/about_roche/roche_worldwide.htm", 
            "phone": "888-662-6728 (U.S. Only)"
        }, 
        "overall_official": {
            "affiliation": "Hoffmann-La Roche", 
            "last_name": "Clinical Trials", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Romania: National Agency for Medicines and Medical Devices"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "August 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Treatment patterns in clinical practice: Number of treatment cycles received", 
            "safety_issue": "No", 
            "time_frame": "approximately 3 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01724294"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Event-free survival", 
                "safety_issue": "No", 
                "time_frame": "approximately 3 years"
            }, 
            {
                "measure": "Response rates", 
                "safety_issue": "No", 
                "time_frame": "approximately 3 years"
            }, 
            {
                "measure": "Safety: Incidence of adverse events", 
                "safety_issue": "No", 
                "time_frame": "approximately 3 years"
            }
        ], 
        "source": "Hoffmann-La Roche", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hoffmann-La Roche", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2012", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "February 2014"
    }
}